论文部分内容阅读
目的探讨依达拉奉联合降纤酶治疗急性脑梗死的临床疗效。方法选取2012年11月至2013年11月收治急性脑梗死患者84例,所有患者均采用丹参注射液20 ml+0.9%氯化钠溶液250ml,静脉滴注,口服肠溶阿司匹林。同时根据患者个体病情使用降压药物及脱水剂配合治疗。将患者分为两组,其中对照组42例,在此基础上给予降纤酶静脉滴注;治疗组42例,在对照组基础上给予依达拉奉,静脉滴注。观察两组患者临床疗效和治疗前后神经功能缺损程度、血浆纤维蛋白原含量变化情况。结果治疗组的临床疗效明显优于对照组(P<0.05);与治疗前相比,治疗组神经功能损伤程度的改善情况优于对照组;两组血浆纤维蛋白原含量治疗前后比较,差异有统计学意义(P<0.05)。结论依达拉奉联合降纤酶治疗急性脑梗死具有明显临床疗效,较单用降纤酶治疗效果更好。
Objective To investigate the clinical efficacy of edaravone combined with defibrase in the treatment of acute cerebral infarction. Methods Eighty-four patients with acute cerebral infarction were selected from November 2012 to November 2013. All patients received 250ml Salvia miltiorrhiza injection (20ml + 0.9% sodium chloride solution), intravenous infusion and oral enteric-coated aspirin. At the same time according to the patient’s condition to use antihypertensive drugs and dehydration agent with the treatment. The patients were divided into two groups, of which 42 cases in the control group were given intravenous infusion of defibrase; 42 cases in the treatment group were given edaravone intravenously on the basis of the control group. The clinical efficacy and the degree of neurological deficits in both groups before and after treatment were observed. The changes of plasma fibrinogen content were observed. Results Compared with the control group, the clinical efficacy of the treatment group was significantly better than that of the control group (P <0.05). Compared with the control group before treatment, the improvement of the degree of neurological impairment in the treatment group was better than that of the control group. There were significant differences in the levels of plasma fibrinogen between the two groups before and after treatment Statistical significance (P <0.05). Conclusion Edaravone combined with defibrase in the treatment of acute cerebral infarction has a significant clinical effect, compared with single defibrase treatment effect is better.